Research Articles
Off-Target Sequencing Explained: A Complete Guide to Targeted Genomic Safety Assessment in Drug Development
This guide provides researchers, scientists, and drug development professionals with a comprehensive framework for designing and executing targeted off-target sequencing analyses.
GenomePAM Analysis: How Chromatin Accessibility Dictates CRISPR-Cas9 PAM Sequence Efficiency
This article provides a comprehensive guide for researchers and drug development professionals on utilizing GenomePAM to analyze the critical relationship between chromatin accessibility and Protospacer Adjacent Motif (PAM) sequence efficiency.
PAM Requirements Compared: Cas9 vs. Cas12a (Cpf1) - A Complete Guide for Genome Engineers
This comprehensive article details the fundamental differences in Protospacer Adjacent Motif (PAM) requirements between the CRISPR nucleases Cas9 and Cas12a, with direct implications for experimental design and therapeutic development.
Cas Nuclease Showdown: Unprecedented Fidelity Comparison Across Thousands of Genomic Sites Using GenomePAM
This comprehensive analysis provides a systematic, large-scale evaluation of the editing fidelity of key Cas nucleases (including SpCas9, SpCas9-HF1, eSpCas9, xCas9, Cas12a, and hyper-accurate variants) across thousands of diverse genomic...
NAG vs. NGG PAM: A Comprehensive Analysis of Off-Target Effects in CRISPR-Cas9 Editing
This article provides a detailed comparative analysis of off-target editing rates between the canonical NGG Protospacer Adjacent Motif (PAM) and the non-canonical NAG PAM for CRISPR-Cas9 systems.
Choosing the Right Cas Nuclease: A Strategic Guide to PAM Availability for CRISPR Genome Editing
This guide provides a comprehensive, actionable framework for selecting Cas nucleases based on Protospacer Adjacent Motif (PAM) availability in target genomes.
ChIP-seq for dCas9 Binding Sites: A Complete Guide for Epigenetic Researchers and Drug Developers
This comprehensive guide provides researchers, scientists, and drug development professionals with a complete framework for utilizing ChIP-seq to map dCas9 binding sites.
Casgevy vs. Lyfgenia: A Comprehensive Efficacy & Safety Profile Analysis for Sickle Cell Disease Gene Therapies
This article provides a detailed, data-driven comparison of the two recently FDA-approved gene therapies for sickle cell disease (SCD), Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel).
Casgevy (exa-cel) Sickle Cell Disease Clinical Trial Results: A Landmark Analysis for CRISPR Therapeutics
This article provides a comprehensive, technical analysis of the clinical trial results for Casgevy (exagamglogene autotemcel or exa-cel), the first CRISPR/Cas9-based gene-editing therapy approved for sickle cell disease.
Cas9 vs TALEN vs ZFN: A 2024 Comparison of Gene Editing Efficiency, Applications, and Best Practices
This article provides researchers, scientists, and drug development professionals with a comprehensive, current comparison of the three primary programmable nuclease platforms: CRISPR-Cas9, TALENs, and ZFNs.